Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

about

Recent clinical trials of cancer immunogene therapy in companion animals.Cancer-type dependent expression of CK2 transcripts.

P2860

Q33711518-8DD896E7-0BA7-46EF-BF10-26F5296CB25E Q47114281-ECC89E8B-31BC-4B09-98D1-2824D5152F63

P2860

Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

Item

http://www.wikidata.org/entity/Q38740809

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Therapeutic Targeting of Prote ...... Model of Head and Neck Cancer.

@en

type

Item

label

Therapeutic Targeting of Prote ...... Model of Head and Neck Cancer.

@en

prefLabel

Therapeutic Targeting of Prote ...... Model of Head and Neck Cancer.

@en

P1476

Therapeutic Targeting of Prote ...... Model of Head and Neck Cancer.

@en

P2093

Betsy T Kren

http://www.w3.org/2001/XMLSchema#string

Gretchen M Unger

http://www.w3.org/2001/XMLSchema#string

Ingrid Cornax

http://www.w3.org/2001/XMLSchema#string

Khalil Ahmed

http://www.w3.org/2001/XMLSchema#string

M Gerard O'Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice

CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Overexpression of nuclear protein kinase CK2 α catalytic subunit (CK2α) as a poor prognosticator in human colorectal cancer.

Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Emergence of protein kinase CK2 as a key target in cancer therapy

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

P304

80-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUMC.2017.008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jaime Modiano

Claire M Cannon

J H Trembley

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28335614

http://www.w3.org/2001/XMLSchema#string

P932

5510041

http://www.w3.org/2001/XMLSchema#string

Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

about

P2860

P2860

Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932